--- title: "Molecular Diagnostics 13Fs: Natera, Exact, Guardant, Veracyte" type: learn slug: molecular-diagnostics-13f-ntra-exas-gh-decoder canonical_url: https://13finsight.com/learn/molecular-diagnostics-13f-ntra-exas-gh-decoder published_at: 2026-05-16T05:02:42.017Z updated_at: 2026-05-16T05:02:47.215Z author: Sarah Mitchell author_title: Education Editor author_url: https://13finsight.com/authors/sarah-mitchell word_count: 392 locale: en source: 13F Insight --- # Molecular Diagnostics 13Fs: Natera, Exact, Guardant, Veracyte > Natera, Exact Sciences, Guardant Health, Veracyte, and Myriad Genetics anchor US molecular diagnostics 13F positioning. Reimbursement coverage cycles, screening market expansion, liquid biopsy adoption, and emerging multi-cancer detection drive distinctive institutional patterns. US molecular diagnostics equities form a distinctive innovation-driven healthcare corner of institutional 13F positioning. Natera (NTRA), Exact Sciences (EXAS), Guardant Health (GH), Veracyte (VCYT), and Myriad Genetics (MYGN) anchor the cohort. Multi-year reimbursement coverage cycles, screening market expansion, liquid biopsy adoption, and emerging multi-cancer early detection drive distinctive institutional patterns. Reading molecular diagnostics 13F positioning requires understanding the reimbursement framework plus the multi-year screening adoption cycle dynamics.The molecular diagnostics business modelMolecular diagnostics faces four primary economic drivers:Reimbursement coverage cycles. Multi-year CMS plus commercial payor coverage decisions drive test volume plus pricing. Multi-year coverage policy development drives long-cycle operator economics.Screening market expansion. Multi-year colorectal cancer screening (Exact Sciences Cologuard), non-invasive prenatal testing (Natera Panorama), expanded carrier screening, plus emerging multi-cancer detection drive market expansion.Liquid biopsy adoption. Multi-year liquid biopsy adoption for cancer recurrence monitoring (Natera Signatera, Guardant Reveal, Exact Sciences Oncodetect) drives recurring revenue.Multi-cancer early detection. Emerging multi-cancer early detection (Grail Galleri, Exact Sciences Cancerguard, Natera Cancer Detection) drives long-cycle screening market expansion.Major US molecular diagnostics namesNatera (NTRA)Diversified across non-invasive prenatal testing (Panorama), carrier screening (Horizon), oncology liquid biopsy (Signatera), plus emerging multi-cancer detection. Multi-year operational scaling.Exact Sciences (EXAS)Cologuard (colorectal cancer screening) franchise leader plus emerging Oncotype DX (breast cancer recurrence) plus Oncodetect liquid biopsy plus emerging multi-cancer detection (Cancerguard).Guardant Health (GH)Liquid biopsy leader (Guardant360 tumor profiling, Reveal recurrence monitoring) plus emerging Shield (colorectal cancer screening). Multi-year liquid biopsy franchise.Veracyte (VCYT)Diversified molecular diagnostics across thyroid (Afirma), lung (Percepta), urology (Decipher), idiopathic pulmonary fibrosis (Envisia). Multi-decade specialty diagnostics franchise.Myriad Genetics (MYGN)Diversified across hereditary cancer (BRACAnalysis CDx), mental health (GeneSight), prenatal (Foresight). Multi-year operational restructuring.How institutional managers position around molecular diagnosticsThree patterns:Pattern 1: Diversified-platform concentrationNTRA-concentrated growth manager positions reflect diversified molecular diagnostics platform thesis.Pattern 2: Screening-franchise positioningEXAS-concentrated active manager positions reflect Cologuard plus emerging screening franchise thesis.Pattern 3: Liquid-biopsy positioningGH-concentrated active manager positions reflect liquid biopsy franchise plus emerging screening thesis.How to read molecular diagnostics 13F positioningThree rules:Rule 1: Identify product mixEach operator's product mix determines reimbursement plus growth dynamics.Rule 2: Watch CMS coverage decisionsMulti-year CMS coverage decisions drive multi-quarter visibility.Rule 3: Cross-check Phase 3 dataMulti-year Phase 3 readouts plus FDA approvals drive operator economics.What molecular diagnostics positioning signalsDiversified-platform conviction. Concentrated NTRA positions signal diversified platform thesis.Screening-franchise conviction. Concentrated EXAS positions signal screening franchise thesis.Liquid-biopsy conviction. Concentrated GH positions signal liquid biopsy thesis.For real-time tracking of molecular diagnostics 13F activity, see the institutional signals feed. ## FAQ ### What are the major US molecular diagnostics companies? Five major US molecular diagnostics: (1) Natera (NTRA) — prenatal testing (Panorama), carrier screening (Horizon), oncology liquid biopsy (Signatera); (2) Exact Sciences (EXAS) — Cologuard colorectal screening, Oncotype DX, Oncodetect liquid biopsy; (3) Guardant Health (GH) — Guardant360 plus Reveal plus Shield colorectal screening; (4) Veracyte (VCYT) — thyroid, lung, urology, pulmonary specialty diagnostics; (5) Myriad Genetics (MYGN) — hereditary cancer plus mental health. ### How does reimbursement coverage work in diagnostics? Multi-year CMS plus commercial payor coverage decisions drive molecular diagnostics test volume plus pricing. CMS National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), plus commercial payor coverage policies determine reimbursement. Multi-year coverage policy development plus emerging coverage drives operator economics. Reading coverage policy disclosure drives institutional positioning. ### What is Cologuard's franchise position? Exact Sciences' Cologuard operates colorectal cancer screening franchise through stool-based DNA testing. Multi-year market expansion plus CMS plus commercial coverage drove substantial revenue growth. Multi-year guidelines update (US Preventive Services Task Force, ACS) plus emerging Cologuard Plus (next-generation) drive market positioning. Competitive pressure from Guardant Shield (blood-based) plus traditional colonoscopy. Multi-year franchise economics drive positioning. ### What is liquid biopsy? Liquid biopsy detects cancer-related genetic material in blood plasma through DNA, RNA, or protein analysis. Multi-year applications include tumor profiling (Guardant360 for treatment selection), recurrence monitoring (Natera Signatera, Guardant Reveal, Exact Oncodetect for surveillance), plus emerging multi-cancer early detection. Multi-year reimbursement adoption plus emerging applications drive market expansion. Reading liquid biopsy adoption drives positioning. ### What is multi-cancer early detection? Multi-cancer early detection (MCED) tests screen for multiple cancer types in single blood test through liquid biopsy approach. Major MCED operators include Grail Galleri (separated from Illumina), Exact Sciences Cancerguard, Natera Cancer Detection, plus emerging entrants. Multi-year regulatory approval pathway plus reimbursement development plus clinical evidence generation drive multi-year commercial adoption. Reading MCED milestones drives positioning. ### What signals molecular diagnostics cycle inflections? Four signals: (1) CMS plus commercial coverage decisions; (2) Phase 3 clinical readouts plus FDA approvals; (3) test volume disclosure plus emerging product launches; (4) M&A activity reshaping franchise positions. Concentrated 13F changes around these signals reveal manager cycle reading. --- Source: 13F Insight — https://13finsight.com/learn/molecular-diagnostics-13f-ntra-exas-gh-decoder Author: Sarah Mitchell — https://13finsight.com/authors/sarah-mitchell Last updated: 2026-05-16T05:02:47.215Z